medigraphic.com
ISSN 1729-519X (Print)

2021, Number 5

<< Back Next >>

Revista Habanera de Ciencias Médicas 2021; 20 (5)

Antineutrophil cytoplasmic autoantibodies and clinical activity in Cuban patients with rheumatoid arthritis

Martínez TG, Torres RB, Sánchez RV

Language: Spanish
References: 22
Page: 1-7
PDF size: 425.57 Kb.


ABSTRACT

Introduction: Antibodies against neutrophil cytoplasm are normally detected in patients with vasculitis. Although these antibodies can be present in a wide number of diseases associated with inflammatory and autoimmune conditions such as rheumatoid arthritis, their clinical significance has not been demonstrated.
Objective: To evaluate the usefulness of different antigenic specificities of antibodies against neutrophil cytoplasm to measure the clinical activity in Cuban patients with rheumatoid arthritis.
Material and Methods: A cross-sectional study was conducted on 77 Cuban patients with rheumatoid arthritis. Erythrocyte sedimentation rate, C-reactive protein, the clinical indicator of disease activity, anti-citrullinated protein antibodies, rheumatoid factor, and antibodies against neutrophil cytoplasm against different specificities were determined.
Results: The largest number of patients with elevated disease activity (> 5.1) belonged to the group of antibodies against neutrophil cytoplasm positive patients (p=0.0364). Patients with anti-lactoferrin antibodies had higher disease activity values ​​(p=0.0304). Through multivariate analysis, the influence of positive anti-lysozyme antibodies (p=0.0391), of double positivity of anti-citrullinated protein and anti-lactoferrin antibodies (p=0.0282), as well as that of double positivity of anti-citrullinated protein and anti-elastin antibodies (p=0.0182) on disease activity were demonstrated.
Conclusion: The antibodies against neutrophil cytoplasm that recognize the antigenic specificities of lysozyme, lactoferrin and elastin are related to higher clinical activity in patients with rheumatoid arthritis.


REFERENCES

  1. Csernok E. The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis. Antibodies (Basel) [Internet]. 2019 [Citado 19/09/2018];8(2):[Aprox. 11 p.]. Disponible en: http://doi.org/10.3390/antib8020031

  2. Martínez G, Torres B, Rangel S, Sánchez V, Ramos MA, Abreu N. Antineutrophil cytoplasm antibody: positivity and clinical correlation. Reumatol Clin. 2015;11(1):17-21.

  3. Grau RG. Drug-Induced Vasculitis: New Insights and a Changing Line up of Suspects. Curr Rheumatol Rep. 2015;17:71-81.

  4. Sy A, Khalidi N, Dehghan N, Barra L, Carette S, Cuthbertson D, et al. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016; 45: 475-82.

  5. Philipponnet C, Garrouste C, Le Guenno G, Cartery C, Guillevin L, Boa JJ et al. Antineutrophilic cytoplasmic antibody-associated vasculitis and malignant hemopathies, a retrospective study of 16 cases. Jt. Bone Spine. 2017, 84:51-57.

  6. Talor MV, Stone H, Stebbing J, Barin N, Rose R, Burek CL. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol. 2007;150:42-48.

  7. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183-96.

  8. Ferraccioli G, Tolusso B, Fedele AL, Gremese E. Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES RMD Open [Internet]. 2016 [Citado 29/12/2018];2(1):[Aprox. 3 p.]. Disponible en: http://doi.org/10.1136/rmdopen-2016-000263

  9. Fox DA. Etiology of rheumatoid arthritis: A historical and evidence-based perspective. En: Chung KC. Clinical management of the rheumatoid hand, wrist, and elbow. Suiza: Springer International Publishing; 2016. p. 13-19.

  10. Martínez G, Feist E, Martiatu M, Garay H, Torres B. Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in Cuban patients with early rheumatoid arthritis. Rheumatology International. 2020;40:1873-81.

  11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-78.

  12. Kida I, Kobayashi S, Takeuchi K, Tsuda H, Hashimoto H, Takasaki Y. Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese pacientes with rheumatoid arthritis. Mod Rheumatol. 2011;21(1):43-50.

  13. Prevoo MLL, Van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte BA, van Riel PL. Modified disease activity scores that include twentyeight- joint counts. Arthritis Rheum. 1995;38:44-8.

  14. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects [Internet]. Francia: World Medical Association; 2013 [Citado 18/11/2017];310(20):[Aprox. 7 p.]. Disponible en: Disponible en: http://www.wma.net/en/30publications/10policies/b3/index.html

  15. Shida H, Nakazawa D, Tateyama Y, Miyoshi A, Kusunoki Y, Hattanda F, et al. The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Pacientes and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation. Front Immunol [Internet]. 2016 [Citado 13/10/2019];7:[Aprox. 7 p.]. Disponible en: http://doi.org/10.3389/fimmu.2016.00636

  16. Manolova IM. Anti-lactoferrin antibodies in patients with connective tissue diseases. Folia Med (Plovdiv). 2003;45:25-30.

  17. Okubo K, Kamiya M, Urano Y, Nishi H, Herter JM, Mayadas T, et al. Lactoferrin suppresses neutrophil extracellular traps release in inflammation. EBioMedicine. 2016; 10:204-15.

  18. Fousert E, Toes R, Desai J, Fousert E, Toes R, Desai J. Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses. Cells. 2020; 9:915-35.

  19. Yang H, Biermann MH, Brauner JM, Liu Y, Zhao Y, Herrmann M. New insights into neutrophil extracellular traps:mechanisms of formation and role in inflammation. Front Immunol [Internet]. 2016 [Citado 18/10/2019]; 7:[Aprox. 8 p.]. Disponible en: http://doi.org/10.3389/fimmu.2016.00302

  20. Sakkas LI, Daoussis D, Liossis SN, Bogdanos DP. The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. Front Microbiol [Internet]. 2017 [Citado 28/11/2019]; 8:[Aprox. 9 p.]. Disponible en: http://doi.org/10.3389/fmicb.2017.01853

  21. Haridas V, Haridas K. Rheumatoid arthritis with ANCA associated vasculitis. IJRCI [Internet]. 2018 [Citado 29/12/2019];6(1):[Aprox. 5 p.]. Disponible en: http://doi.org/10.15305/ijrci/v6i1/273

  22. Spoerl D, Pers YM, Jorgensen C. Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: two case reports and review of literature. Allergy Asthma Clin Immunol [Internet]. 2012 [Citado 10/02/2016];8(1):[Aprox. 5 p.]. Disponible en: http://www.aacijournal.com/content/8/1/19




2020     |     www.medigraphic.com